That's interesting archive
New Zealand is one of the few countries in the world using cilazapril. To avoid potential supply issues, PHARMAC is no longer funding cilazapril for new patients. Dr Chris Ellis discusses management options in this article from New Zealand Doctor Rata Aotearoa.
The Council of Medical Colleges (CMC), in partnership with Te ORA, commissioned this report to better understand the actions medical colleges are taking to support cultural safety and health equity. It also examines how Māori fellows and trainees have experienced the training programmes and support offered by medical colleges.
The report aims to provide both a snapshot on progress and a knowledge base that will support the evolution of vocational medical training towards cultural safety. It shows that many colleges are undertaking activities with the aim of supporting health equity, and we are all on varying stages of this journey. Importantly, the report also highlights the cultural loading that Māori doctors experience consistently across all medical specialties.
From 1 May, cilazapril will no longer be funded for new patients. This article from bpac offers helpful advice on appropriate alternatives.
Media release from Healthier Lives National Science Challenge and Edgar Diabetes and Obesity Research
This media release outlines a report titled "The Economic and Social Cost of Type 2 Diabetes". The report found that around 600 amputations could be avoided every year in New Zealand if better foot screening and podiatry services were made available for everyone with type 2 diabetes.
Written by Sally Murphy, Reporter.
This article from RNZ outlines the concerning conclusions of a PwC report commissioned by Diabetes New Zealand, the University of Otago's Edgar Diabetes and Obesity Research Centre and Healthier Lives National Science Challenge. The report found that the number of people with type 2 diabetes in New Zealand could increase by 90% across the next two decades.
Written by Dr Vicki Mount with expert review by Dr Ryan Paul
This Goodfellow MedCase considers the place of empagliflozin alongside existing treatments and describes how to safely start treatment.
The first-ever New Zealand COPD guidelines have been published. Developed by the Asthma and Respiratory Foundation and led by Dr Stuart Jones and Professor Bob Hancox, these guidelines clearly lay out the recommendations for assessment and management of COPD.
Joanna Hikaka, Rhys Jones, Carmel Hughes, Matin J. Connolly and Nataly Martini. Drugs & Aging. Online ahead of print. January 2021.
This review from the University of Auckland examines ethnic variation in the quality use of medicines between Māori and non-Māori older adult populations in NZ. It identifies that inequities in quality medicines use exist and provides a starting point to develop pro-equity solutions.
The Tongan Health Society is working on an innovative approach to underpin best practice models for patients with diabetes who are on maximum oral hypoglycaemic medication to start insulin therapy when they are hesitant to do so.
This article answers some of the frequently asked questions about the newly funded type 2 diabetes medicine - empagliflozin (with and without metformin) and dulaglutide, which is to be funded as soon a possible following Medsafe approval.